April 1986

Clinical Experience With Timolol Maleate Monotherapy of Hypertension

Author Affiliations

From the Philadelphia Association for Clinical Trials (PACT), 3440 Market St, Philadelphia (Dr Bannon, Ms Stewart, and Dr Schrogie); and Data and Information Systems Center of the University City Science Center, 3508 Market St, Philadelphia (Dr DeLisser).

Arch Intern Med. 1986;146(4):654-657. doi:10.1001/archinte.1986.00360160056006

• β-Adrenergic blocking drugs are gaining acceptance as initial therapy for patients with mild to moderate hypertension. In a postmarketing surveillance study, 5,190 hypertensive patients received timolol maleate monotherapy and were evaluated by 1,355 physicians. A total of 1,057 patients did not complete the study: 28% of these patients experienced an adverse event. Mean systolic and diastolic blood pressure readings were reduced 20 and 13 mm Hg, respectively. Mean diastolic blood pressure was reduced 11% for patients with mild hypertension; larger mean reductions were noted for patients with moderate (17%) and severe hypertension (22%). The effect in black and elderly patients was less than in other groups. Although 22% of all patients experienced an adverse event, less than 2.2% of all patients experienced events related to β-adrenergic blockade, ie, respiratory difficulty, heart failure, bradycardia, and cold extremities. Fatigue, dizziness, and nausea were the most frequently reported adverse events requiring discontinuation of therapy. Timolol monotherapy is a well-tolerated and effective treatment for a broad range of hypertensive patients.

(Arch Intern Med 1986;146:654-657)